Organogenesis Holdings Beheer
Beheer criteriumcontroles 2/4
De CEO Organogenesis Holdings is Gary Gillheeney, benoemd in Jan2014, heeft een ambtstermijn van 10.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.24M, bestaande uit 14.6% salaris en 85.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.63% van de aandelen van het bedrijf, ter waarde $ 2.34M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.2 jaar en 4 jaar.
Belangrijke informatie
Gary Gillheeney
Algemeen directeur
US$6.2m
Totale compensatie
| Percentage CEO-salaris | 14.6% |
| Dienstverband CEO | 10.8yrs |
| Eigendom CEO | 0.6% |
| Management gemiddelde ambtstermijn | 7.2yrs |
| Gemiddelde ambtstermijn bestuur | 4yrs |
Recente managementupdates
Recent updates
Organogenesis: Lurking Disruption With Recovery To Follow
Oct 15Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S
Sep 09
We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope
Jun 15Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst
Jun 10Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality
May 21Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price
May 01Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?
Apr 10These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well
Jan 04Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?
May 31Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?
Jan 19Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio
Oct 18Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly
Sep 23Organogenesis gets FDA clearance for PuraPly MZ for wound healing
Aug 15Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors
Jul 28Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly
Jun 10Organogenesis Holdings: What Now
May 18The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet
Mar 31These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well
Mar 04Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$17m |
| Mar 31 2024 | n/a | n/a | US$6m |
| Dec 31 2023 | US$6m | US$909k | US$5m |
| Sep 30 2023 | n/a | n/a | US$13m |
| Jun 30 2023 | n/a | n/a | US$10m |
| Mar 31 2023 | n/a | n/a | US$13m |
| Dec 31 2022 | US$6m | US$883k | US$16m |
| Sep 30 2022 | n/a | n/a | US$59m |
| Jun 30 2022 | n/a | n/a | US$71m |
| Mar 31 2022 | n/a | n/a | US$83m |
| Dec 31 2021 | US$4m | US$835k | US$94m |
| Sep 30 2021 | n/a | n/a | US$62m |
| Jun 30 2021 | n/a | n/a | US$69m |
| Mar 31 2021 | n/a | n/a | US$43m |
| Dec 31 2020 | US$3m | US$823k | US$17m |
| Sep 30 2020 | n/a | n/a | -US$5m |
| Jun 30 2020 | n/a | n/a | -US$37m |
| Mar 31 2020 | n/a | n/a | -US$42m |
| Dec 31 2019 | US$1m | US$819k | -US$39m |
| Sep 30 2019 | n/a | n/a | -US$46m |
| Jun 30 2019 | n/a | n/a | -US$48m |
| Mar 31 2019 | n/a | n/a | -US$58m |
| Dec 31 2018 | US$3m | US$798k | -US$65m |
| Sep 30 2018 | n/a | n/a | -US$60m |
| Jun 30 2018 | n/a | n/a | -US$52m |
| Mar 31 2018 | n/a | n/a | -US$32m |
| Dec 31 2017 | US$1m | US$780k | -US$9m |
Compensatie versus markt: De totale vergoeding ($USD 6.24M ) Gary } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.40M ).
Compensatie versus inkomsten: De vergoeding van Gary is gestegen terwijl het bedrijf verliesgevend is.
CEO
Gary Gillheeney (69 yo)
10.8yrs
Tenure
US$6,244,671
Compensatie
Mr. Gary S. Gillheeney, Sr. has been the Chief Executive Officer and President of Organogenesis Holdings Inc. since 2014 and has been its Director since December 10, 2018 & serves as its Chair of the Board...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 10.8yrs | US$6.24m | 0.63% $ 2.3m | |
| Chief Financial Officer | 3.8yrs | US$1.63m | 0.048% $ 177.5k | |
| Chief Operating Officer | 7.2yrs | US$2.16m | 0.26% $ 964.8k | |
| Chief Administrative & Legal Officer | 7.8yrs | US$1.99m | 0.063% $ 233.3k | |
| Chief Commercial Officer | 7.2yrs | US$1.92m | 0.078% $ 288.6k | |
| Secretary | no data | geen gegevens | geen gegevens | |
| Vice President of Strategy | 3.8yrs | geen gegevens | 0.11% $ 388.5k |
7.2yrs
Gemiddelde duur
57.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ORGO is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.2 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 5.9yrs | US$6.24m | 0.63% $ 2.3m | |
| Director | 21.8yrs | geen gegevens | 11.29% $ 41.6m | |
| Director | 21.8yrs | geen gegevens | 11.5% $ 42.4m | |
| Lead Independent Director | 5.9yrs | US$291.46k | 0.10% $ 379.7k | |
| Director | 4yrs | geen gegevens | geen gegevens | |
| Independent Director | 3.5yrs | US$265.00k | 0.068% $ 249.7k | |
| Independent Director | 2.5yrs | US$226.98k | 0.068% $ 249.2k | |
| Independent Director | 3yrs | US$240.00k | 0.071% $ 260.9k | |
| Director | 4yrs | geen gegevens | geen gegevens | |
| Independent Director | 2.8yrs | US$230.52k | geen gegevens | |
| Independent Director | 2.5yrs | US$226.98k | 0.068% $ 249.2k |
4.0yrs
Gemiddelde duur
59yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ORGO wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).